12 Lung Cancer Clinical Trials in Gilbert, AZ (2026)

Q: How do I join a clinical trial in Gilbert?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the Gilbert research site will contact you.

Recruiting Lung Cancer Studies in Gilbert

NCT07222566Recruiting

Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

This study is being done to find out if a new medicine called PF-08634404, when given with chemotherapy, works better than the present standard treatment (pembrolizumab with chemotherapy) for adults w...

Gilbert, AZPHASE31,410 participantsPfizer

View Study Details

NCT06119581Recruiting

A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

The purpose of this study is to assess if adding LY3537982 (olomorasib) in combination with standard of care anti-cancer drugs is more effective than standard of care in participants with untreated ad...

Gilbert, AZPHASE31,264 participantsEli Lilly and Company

View Study Details

NCT04267848Recruiting

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

This phase III ALCHEMIST treatment trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by...

Gilbert, AZPHASE31,210 participantsNational Cancer Institute (NCI)

View Study Details

NCT06623422Recruiting

A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

The goal of this study is to learn if people who receive intismeran autogene and pembrolizumab after surgery are cancer-free longer than people who receive placebo and pembrolizumab. Researchers want ...

Gilbert, AZPHASE3680 participantsMerck Sharp & Dohme LLC

View Study Details

NCT06162221Recruiting

Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC

The purpose of this platform study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of novel RAS(ON) inhibitors as a monotherapy or combined with Stan...

Gilbert, AZPHASE1616 participantsRevolution Medicines, Inc.

View Study Details

NCT05786924Recruiting

Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

BDTX-4933-101 is a first-in-human, open-label, Phase 1/2 dose escalation, dose optimization and expansion study designed to evaluate the safety and tolerability of S241656 as monotherapy and in combin...

Gilbert, AZPHASE1554 participantsInstitut de Recherches Internationales Servier

View Study Details

NCT04165070Recruiting

KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)

The purpose of this study is to assess the efficacy and safety of pembrolizumab (MK-3475) with or without chemotherapy in combination with vibostolimab (MK-7684), boserolimab (MK-5890), MK-4830, MK-04...

Gilbert, AZPHASE1450 participantsMerck Sharp & Dohme LLC

View Study Details

NCT05099172Recruiting

First in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and/or Human Epidermal Growth Factor Receptor 2 (HER2)

Researchers are looking for a better way to treat people who have advanced non-small cell lung cancer (NSCLC), a group of lung cancers that have spread to nearby tissues or to other parts of the body....

Gilbert, AZPHASE1400 participantsBayer

View Study Details

NCT07291037Recruiting

Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations

TROPION-Lung17 will measure the efficacy and safety of datopotamab deruxtecan (Dato-DXd) compared with docetaxel in patients with trophoblast cell surface protein 2 (TROP2) positive advanced or metast...

Gilbert, AZPHASE3400 participantsAstraZeneca

View Study Details

NCT07037758Recruiting

A Study of Tarlatamab in Combination With AB248 in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-311)

The primary objective for dose exploration and dose expansion is to evaluate the safety and tolerability of tarlatamab in combination with AB248. The primary objective for dose exploration only is to...

Gilbert, AZPHASE1380 participantsAmgen

View Study Details

NCT04614103Recruiting

Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer

This is a prospective, open-label, multi-cohort, non-randomized, multicenter phase 2 study evaluating LN-145 in patients with metastatic non-small-cell lung cancer...

Gilbert, AZPHASE2170 participantsIovance Biotherapeutics, Inc.

View Study Details

NCT05877599Recruiting

A Study of NT-175 in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation

Phase I Study of NT-175, an autologous T cell therapy product genetically engineered to express an HLA-A\*02:01-restricted T cell receptor (TCR), targeting TP53 R175H mutant solid tumors....

Gilbert, AZPHASE145 participantsAstraZeneca

View Study Details

About Lung Cancer Clinical Trials in Gilbert

Lung cancer is the leading cause of cancer death worldwide, starting in the cells of the lungs. The two main types are non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). Treatments include surgery, chemotherapy, radiation, immunotherapy, and targeted drugs.

There are currently 12 lung cancer clinical trials recruiting participants in Gilbert, AZ. These studies are seeking a combined 7,579 participants. Research is being sponsored by Pfizer, Eli Lilly and Company, National Cancer Institute (NCI) and 7 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Lung Cancer Clinical Trials in Gilbert — FAQ

Are there lung cancer clinical trials in Gilbert?

Yes, there are 12 lung cancer clinical trials currently recruiting in Gilbert, AZ. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Gilbert?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Gilbert research site will contact you about next steps.

Are clinical trials in Gilbert free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Gilbert studies also compensate for your time and travel.

What lung cancer treatments are being tested?

The 12 active trials in Gilbert are testing new therapies including novel drugs, biologics, and treatment approaches for lung cancer.

Data updated July 21, 2026 from ClinicalTrials.gov